Date: 2014-08-19
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the Alzheimer’s Association International Conference in Copenhagen, Denmark
Company: Stemedica International (Switzerland)
Product: allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs)
Action
mechanism: Stemedica’s bone-marrow-derived, allogeneic ischemia-tolerant mesenchymal stem cells (itMSCs) are grown under hypoxic conditions. In vitro experiments demonstrate cells that are exposed to hypoxic conditions show greater homing and engraftment than cells grown under normoxic conditions. Compared to other mesenchymal stem cells, itMSCs secrete higher levels of growth factors and other important proteins associated with neoangiogenesis and healing.
Disease: Alzheimer’s disease
Therapeutic area: Neurodegenerative diseases
Country:
Trial details:
Latest
news: * On August 19, 2014, Stemedica International, a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, announced the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease. The results demonstrated a greater than 30-percent decrease in amyloid beta (Abeta) plaques in the brain of transgenic animals treated with Stemedica itMSCs compared to the control group that were treated with lactated Ringer’s solution (LRS). These results were achieved during a two-year, intensive, pre-clinical research project supported by a grant from the Swiss Commission for Technology and Innovation (CTI). The research was conducted at the Laboratoire d’Optique Biomedicale and headed by Professor Theo Lasser at École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland. The results were presented at the Alzheimer’s Association International Conference in Copenhagen, Denmark, on July 14, 2014. In addition, Dr. Bolmont will share the findings during his talk at the Stem Cells Regenerative Medicine Congress 2014 in Boston, Massachusetts, on Sept. 15 at 2:30 p.m. ET.
